Treadwell, Marsha J. http://orcid.org/0000-0003-0521-1846
Mushiana, Swapandeep
Badawy, Sherif M.
Preiss, Liliana
King, Allison A.
Kroner, Barbara
Chen, Yumei
Glassberg, Jeffrey
Gordeuk, Victor
Shah, Nirmish
Snyder, Angela
Wun, Theodore
,
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL 133948, HL133964, HL133994, HL133997, HL134007, HL 134042)
Article History
Accepted: 21 March 2022
First Online: 21 April 2022
Declarations
:
: Drs. Treadwell, Mushiana, Badawy, Preiss, King, Kroner, Glassberg, Gordeuk, Snyder, Wun and Ms. Chen have none to declare. Dr. Shah receives research funding from Global Blood Therapeutics, is a consultant for Novartis, Emmaus Medical and Forma Therapeutics and a speaker for Global Blood Therapeutics and Novartis.
: This study was approved by the institutional review boards of the participating institutions (Approval Numbers: University of California San Francisco 20–31161; Research Triangle Institute 14157; Washington University, St. Louis 201706016; Mount Sinai PPHS 16–01047; University of Illinois, Chicago 17–061401; Duke University Pro00073506; Augusta University 1078191). The authors certify that all procedures in the study were performed in accordance with the ethical standards as laid down in the 1964 declaration of Helsinki and its latter amendments or comparable ethical standards.
: Informed consent to participate in the study was obtained from all participants.
: Informed consent included agreement to have de-identified data published and disseminated in accordance with publication guidelines for the Sickle Cell Disease Implementation Consortium.